Hussman Strategic Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Hussman Strategic Advisors, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	SELL	$22.72 - $29.68 $408,960 - $534,240	-18,000 Reduced 19.23%	75,600 $2.19 Million
Q2 2023 Aug 03, 2023	BUY	$29.91 - $38.73 $17,946 - $23,237	600 Added 0.65%	93,600 $2.81 Million
Q1 2023 May 04, 2023	SELL	$34.93 - $42.03 $1.08 Million - $1.3 Million	-31,000 Reduced 25.0%	93,000 $3.37 Million
Q3 2022 Nov 02, 2022	SELL	$28.79 - $35.41 $172,740 - $212,459	-6,000 Reduced 4.62%	124,000 $4.2 Million
Q2 2022 Sep 12, 2022	BUY	$25.33 - $34.25 $658,580 - $890,500	26,000 Added 25.0%	130,000 $3.76 Million
Q4 2021 Jan 31, 2022	BUY	$26.37 - $34.22 $290,070 - $376,420	11,000 Added 11.83%	104,000 $3.03 Million
Q2 2021 Aug 03, 2021	SELL	$26.72 - $33.19 $1.36 Million - $1.69 Million	-51,000 Reduced 35.42%	93,000 $2.86 Million
Q1 2021 May 03, 2021	BUY	$24.15 - $31.45 $2.25 Million - $2.92 Million	93,000 Added 182.35%	144,000 $3.77 Million
Q4 2020 Feb 01, 2021	BUY	$17.7 - $25.81 $637,200 - $929,160	36,000 Added 240.0%	51,000 $1.28 Million
Q4 2019 Jan 31, 2020	SELL	$19.93 - $29.13 $199,300 - $291,300	-10,000 Reduced 40.0%	15,000 $356,000
Q2 2019 Jul 31, 2019	SELL	$29.96 - $38.87 $449,400 - $583,050	-15,000 Reduced 37.5%	25,000 $827,000
Q1 2019 May 01, 2019	SELL	$32.77 - $41.99 $819,250 - $1.05 Million	-25,000 Reduced 38.46%	40,000 $1.4 Million
Q4 2018 Feb 01, 2019	BUY	$30.84 - $49.51 $462,600 - $742,650	15,000 Added 30.0%	65,000 $2.16 Million
Q1 2018 May 01, 2018	BUY	$37.15 - $46.9 $1.86 Million - $2.35 Million	50,000 New	50,000 $2.29 Million

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.11B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Hussman Strategic Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Hussman Strategic Advisors, Inc. with notifications on news.